GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (TSXV:TLT) » Definitions » EBIT

Theralase Technologies (TSXV:TLT) EBIT : C$-4.30 Mil (TTM As of Sep. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Theralase Technologies EBIT?

Theralase Technologies's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was C$-0.93 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was C$-4.30 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Theralase Technologies's annualized ROC % for the quarter that ended in Sep. 2024 was -177.09%. Theralase Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -485.10%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Theralase Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -6.81%.


Theralase Technologies EBIT Historical Data

The historical data trend for Theralase Technologies's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralase Technologies EBIT Chart

Theralase Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.40 -5.59 -4.41 -5.21 -4.54

Theralase Technologies Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.01 -0.98 -1.26 -1.13 -0.93

Competitive Comparison of Theralase Technologies's EBIT

For the Medical Devices subindustry, Theralase Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theralase Technologies's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Theralase Technologies's EV-to-EBIT falls into.



Theralase Technologies EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-4.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theralase Technologies  (TSXV:TLT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Theralase Technologies's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-3.796 * ( 1 - 0% )/( (2.16 + 2.127)/ 2 )
=-3.796/2.1435
=-177.09 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Theralase Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-3.728/( ( (0.727 + max(-0.568, 0)) + (0.667 + max(0.143, 0)) )/ 2 )
=-3.728/( ( 0.727 + 0.81 )/ 2 )
=-3.728/0.7685
=-485.10 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.019 + 0.651 + 0.148) - (0.911 + 0 + 0.475)
=-0.568

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.208 + 0.61 + 0.09) - (0.765 + 0 + 0)
=0.143

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Theralase Technologies's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=-4.304/63.172
=-6.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theralase Technologies EBIT Related Terms

Thank you for viewing the detailed overview of Theralase Technologies's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Theralase Technologies Business Description

Traded in Other Exchanges
Address
41 Hollinger Road, Toronto, ON, CAN, M4B 3G4
Theralase Technologies Inc is a clinical-stage pharmaceutical company. It is dedicated to the research and development of light-activated Photo Dynamic Compounds, their associated drug formulations, and technology platforms intended to safely and effectively; treat various cancers, bacteria, and viruses. The Cool Laser Technology division designs, develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle, and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.
Executives
Matthew Thomas Perraton Director
Roger John Dumoulin-white 10% Security Holder, Director, Senior Officer
Kristina Maria Hachey Senior Officer
Arkady Mandel Senior Officer
Guy John Anderson Director
Shawn Shirazi Senior Officer

Theralase Technologies Headlines

From GuruFocus

Top 5 4th Quarter Trades of Rothschild Capital Partners, LLC

By GuruFocus Research GuruFocus Editor 02-15-2023

Pacifica Partners Inc. Buys 4, Sells 1 in 2nd Quarter

By GuruFocus Research GuruFocus Editor 07-23-2022

Rafferty Asset Management, LLC's Top 5 Buys of the 4th Quarter

By GuruFocus Research GuruFocus Editor 02-15-2023

Top 5 3rd Quarter Trades of PINNACLE FINANCIAL PARTNERS INC

By GuruFocus Research GuruFocus Editor 10-31-2022

Top 5 2nd Quarter Trades of K.J. Harrison & Partners Inc

By GuruFocus Research GuruFocus Editor 07-27-2022

Louis Moore Bacon Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor 11-14-2022

Strong Tower Advisory Services Buys 2, Sells 3 in 4th Quarter

By GuruFocus Research GuruFocus Editor 01-21-2023

Top 5 3rd Quarter Trades of Louis Moore Bacon

By GuruFocus Research GuruFocus Editor 11-16-2022

Top 5 4th Quarter Trades of VANTAGEPOINT INVESTMENT ADVISERS LLC

By GuruFocus Research GuruFocus Editor 01-21-2023